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ranging from 63% to 85% and limb salvage from 52% to
87% in patients with ESRD.2-9 Overall survival in these
patients has been consistently poor, which reflects their
decreased life expectancy from multiple causes, including
a high incidence of cardiac disease and infectious and
access complications.10-13 In addition, ESRD has a nega-
tive impact on morbidity, mortality, and survival after
lower extremity amputation.14 The risk/benefit ratio of
infrainguinal arterial reconstruction for limb salvage in
patients with chronic renal failure has thus not been clearly
defined. The purpose of this retrospective review was to
evaluate the perioperative and long-term results of patients
with ESRD undergoing infrainguinal revascularization at a
single institution.
METHODS
Patient population. A retrospective review was per-
formed of all patients undergoing infrainguinal revascular-
ization for limb salvage between December 1994 and
December 1999. During this time period, 461 grafts were
created in 425 limbs in 368 patients. Indications for oper-
ation included tissue loss (284 [62%]), rest pain (141
[30%]), and acute arterial ischemia (36 [8%]). Comorbid
Improvements in the medical management of end-
stage renal disease (ESRD) have allowed more patients to
survive for prolonged periods dependent on renal replace-
ment therapy. The high incidence of atherosclerotic vascu-
lar disease in this population has led to an increased
number of dialysis-dependent patients requiring arterial
reconstruction for limb-threatening infrainguinal vascular
disease.1 Recent reports have documented graft patency
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Introduction: Infrainguinal bypass grafting for limb-threatening ischemia in patients with end-stage renal disease is
generally thought to be associated with increased operative risk and poor long-term outcome. This retrospective study
was undertaken to examine the modern-era, long-term results of infrainguinal bypass grafting in dialysis-dependent
patients.
Methods: Over the past 5 years in a single institution, 425 lower extremities (368 consecutive patients) were revascu-
larized for the indication of limb salvage. Sixty-four patients (82 limbs) were dialysis-dependent at the time of revas-
cularization, and this group was analyzed separately. They exhibited statistically significant higher incidences of diabetes
(83% vs 56%; P < .001), hypertension (91% vs 74%; P < .001), and more distal vascular disease, which required a greater
proportion of proximal anastomoses at the popliteal level (24% vs 11%; P < .01) and distal anastomoses at the
infrapopliteal level (75% vs 65%; P < .05).
Results: Despite the higher prevalence of comorbid conditions and distal disease in patients with renal failure, their peri-
operative 30-day mortality rate remained low (4.9%) and was not significantly different from that in patients with func-
tioning kidneys (2.9%; P = not significant). After a median follow-up of 11 months (range, 0-60 months), the 3-year
autogenous conduit secondary graft patency in patients with renal failure was no different than in patients with func-
tioning kidneys (67% ± 9% vs 64% ± 5%; P = not significant). Nonautogenous conduits in dialysis-dependent patients
exhibited a significantly poorer outcome with only 27% ± 12% remaining secondarily patent at 2 years. As expected,
both limb salvage and patient survival were significantly less in patients with renal faiture, although both exceeded 50%
at 3 years (limb salvage 59% ± 8% vs 68% ± 5%; P < .05; patient survival 60% ± 8% vs 86% ± 4%; P < .001). The often-
quoted phenomenon of limb loss, despite a patent bypass graft, occurred infrequently in this study (n = 3 of 82 limbs).
Conclusion: Infrainguinal revascularization can be performed in dialysis-dependent patients with acceptable periopera-
tive and long-term results, especially in patients in whom adequate autologous conduit is available. (J Vasc Surg
2001;34:27-33.)
risk factors were prevalent including hypertension (279
[77%]), diabetes mellitus (220 [60%]), coronary artery
disease (209 [58%]), and cerebrovascular disease (97
[27%]). Most patients had evidence of atherosclerosis in
multiple vascular beds. Fifty-nine percent of patients
demonstrated significant peripheral vascular disease in the
contralateral extremity ranging from claudication (64
[17%]) to prior contralateral bypass graft (96 [26%]) and
contralateral amputation (44 [12%]).
Sixty-four patients (82 limbs) were dialysis-dependent
at the time of revascularization. This group exhibited sig-
nificantly higher incidences of hypertension (91% vs 74%;
P < .001), diabetes mellitus (83% vs 56%; P < .001), and
coronary artery disease (71% vs 56%; P = .02). There was
no difference between dialysis-dependent and indepen-
dent groups in the incidences of cerebrovascular disease
(20% vs 28%; P = not significant [NS]) or previous coro-
nary artery bypass grafting (19% vs 19%; P = NS). The
presence of clinically overt peripheral vascular disease in
the contralateral leg was not different in the two groups,
with 21% of patients in each group having undergone
prior contralateral infrainguinal bypass grafting and 12% of
dialysis patients and 9% of nondialysis patients having had
contralateral amputation (P = NS). Although all patients
in both groups underwent revascularization for limb sal-
vage indications, patients with ESRD were significantly
more likely to have tissue loss (80% vs 58%; P < .001) than
rest pain or acute ischemia.
Procedures. Infrainguinal bypass grafting was defined
as the creation of a new bypass graft originating distal to the
inguinal ligament including those originating from previ-
ously placed aortofemoral grafts. Procedures involving only
revision of an existing infrainguinal graft were excluded.
“Redo” bypass grafts were included and comprised 22% of
all procedures. Eighty-seven percent (400) of all grafts orig-
inated at the level of the femoral artery. Not surprisingly,
patients with ESRD were significantly more likely to have
infrapopliteal disease manifested by a significantly higher
incidence of popliteal-distal graft placement (Table I). The
use of nonautologous conduits, including polytetrafluo-
roethylene and cryopreserved vein, was equally applied in
both groups. Also equally applied was the use of alternative
autologous conduits such as arm vein, lesser saphenous
vein, superficial femoral vein, and composite vein (Table
II). Inclusion of graft modifications or adjuncts such as ve-
novenostomy (14% vs 16%, P = NS), vein patch angioplasty
(7% vs 5%; P = NS), and distal arteriovenous fistulae (1% vs
1%; P = NS) was similar between the two groups.
Statistics. Variables were compared with the Student
t test, the Wilcoxon test, and the χ2 test, where appropri-
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Fig 1. Cumulative secondary patency of 279 autogenous infrain-
guinal bypass grafts. No significant difference between grafts in
patients with ESRD (56) and functioning kidneys (223). Dashed
lines denote SEM > 10%. ESRD, End-stage renal disease.
Table I. Anastomotic location in 461 infrainguinal
bypass grafting procedures
Patients Patients with 
Graft level with ESRD functioning kidneys
Femoral: above-knee 15 (18%) 101 (27%)
popliteal
Femoral: below-knee 6 (7%) 33 (9%)
popliteal
Femoral: distal 43 (51%) 202 (54%)
Popliteal: distal 20 (24%) 41 (11%)*
*P < .01.
Table II. Conduit type in 461 infrainguinal bypass graft procedures
Conduit Patients with ESRD Patients with functioning kidneys
Greater saphenous vein 39 (46%) 140 (37%)
Polytetrafluoroethylene 24 (29%) 140 (37%)
Composite 10 (12%) 50 (13%)
Arm vein 3 (4%) 21 (6%)
Cryopreserved vein 4 (5%) 14 (4%)
Superficial femoral vein 4 (5%) 6 (2%)
Lesser saphenous vein 0 (0%) 6 (2%)
ate. SPSS 8.0 software (SPSS Inc, Chicago, Ill) was used
for life-table analysis of survival and patency data.
Significance was assigned at P less than .05. Survival, the
patency rate, and the limb salvage rate were presented as
defined by the Ad hoc Committee’s recommended stan-
dards for reports dealing with lower extremity ischemia.15
RESULTS
Despite a higher prevalence of comorbid conditions
and infrapopliteal disease in patients with renal failure, their
perioperative mortality rate remained low (4.9%) and was
not significantly different from that in patients with func-
tioning kidneys (2.9%; P = NS). Major complications
occurred after 9 (11%) of 84 procedures in patients under-
going dialysis and 28 (7%) of 377 procedures in patients
who were not (P = NS). The types of perioperative com-
plications sustained by the two groups were similar, except
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for a slightly higher incidence of myocardial infarction in
the patients with ESRD (Table III). After a median follow-
up of 11 months (range, 0-60 months), 3-year secondary
graft patency for autogenous conduit in patients with renal
failure was 67% ± 9%, which was not significantly different
from that in patients with functioning kidneys (64% ± 5%;
P = NS; Fig 1, Tables IV and V). Nonautogenous conduits
exhibited significantly poorer 2-year patency (27% ± 12% vs
55% ± 6%; P < .05), limb salvage (54% ± 13% vs 72% ± 5%;
P = .01), and survival (54% ± 16% vs 89% ± 4%; P < .001)
in dialysis-dependent patients compared with patients with
functioning kidneys (Fig 2). 
Acute limb salvage was similar in the two groups.
Amputation within the first 30 postoperative days was per-
formed in 6 (7.3%) of 82 limbs in patients undergoing
dialysis and 20 (5.8%) of 343 limbs (P = NS) in patients
with functioning kidneys. In patients with renal failure,
Table III. Perioperative complications
Patients with ESRD Patients with functioning kidneys
30-day mortality 4 (5%) 11 (3%)
Wound infection 8 (10%) 30 (8%)
Graft infection 4 (5%) 6 (2%)
Myocardial infarction 3 (4%) 3 (1%)*
Gastrointestinal hemorrhage 3 (4%) 4 (1%)
Cerebrovascular accident 1 (1%) 5 (1%)
Pneumonia 1 (1%) 6 (2%)
*P < .05.
Table IV. Life table: autogenous grafts in patients with functioning kidneys (223)
Month No. of patients entered No. of failures No. withdrawn Interval patency Cumulative secondary patency % SEM
0-6 223 35 72 81% 81% 0
6-12 116 11 32 89% 72% 1
12-18 73 1 17 98% 71% 1
18-24 55 3 18 93% 67% 1
24-30 34 1 8 97% 64% 2
30-36 25 0 13 100% 64% 3
36-42 12 0 7 100% 64% 5
42-48 5 1 2 75% 48% 10
Table V. Life table: autogenous grafts in patients with ESRD (56)
Month No. of patients entered No. of failures No. withdrawn Interval patency Cumulative secondary patency % SEM
0-6 56 4 24 91% 91% 2
6-12 28 2 4 92% 84% 3
12-18 22 1 7 95% 79% 4
18-24 14 0 1 100% 79% 6
24-30 13 2 1 84% 67% 5
30-36 10 0 3 100% 67% 7
36-42 7 0 4 100% 67% 9
42-48 3 0 1 100% 67% 22
the often-quoted phenomenon of limb loss, despite 
a patent bypass graft,6,9 occurred infrequently in this 
study (3 of 82 limbs vs 11 of 343 limbs; P = NS). Limb
salvage at 3 years was significantly less frequent in dialysis-
dependent patients (59% ± 8% vs 68% ± 5%; P < .05; 
Fig 3). Patients with ESRD initially presenting with rest
pain had a lower rate of limb loss than patients initially
presenting with tissue loss (1 of 15 vs 22 of 67 patients; 
P < .01). Although the decreased limb salvage in patients
with ESRD could be attributed to the higher incidence of
tissue loss as the operative indication, dialysis-dependent
patients with preoperative tissue loss still fared more
poorly than patients with functioning kidneys with the
same degree of preoperative tissue loss (Fig 4). Surpris-
ingly, gangrene or ulcers affecting only the toes were not
associated with a lower rate of limb loss compared with 
tissue loss extending onto the foot or even the ankle 
(72% ± 8% vs 59% ± 8%; P = NS). The requirement for
minor debridement and amputation procedures ranging
from toe amputation to transmetatarsal amputation
among those presenting with tissue loss was not different
between the two groups (45% ± 7% vs 47% ± 3%; P = NS).
As expected, patient survival was significantly less in
patients with renal failure; however, overall survival still
exceeded 50% at 3 years (60% ± 8% vs 86% ± 4%; P < .01;
Fig 5).
DISCUSSION
Improvements in the treatment of ESRD have
enhanced and extended the lives of innumerable patients.
Prolonged survival, however, has also increased the likeli-
hood of peripheral arterial complications including many
specific to this patient population, such as diffuse calcific
arteriopathy,16 immunosuppression complicating minor
wound healing,17 and uremia leading to platelet dysfunc-
tion. In addition to the increase in medical complexity,18
the actual number of patients with ESRD is rising. In the
United States Renal Data System,1 it has been reported
that the number of dialysis-dependent patients exceeded
300,000 in 1998 and will double by the year 2010.
Because more than 20% of patients with ESRD are also
plagued with peripheral arterial insufficiency, there is a siz-
able increase in the population who require vascular surgi-
cal consultation.
The reported clinical results of infrainguinal bypass
grafting in patients with ESRD vary widely. In 1988,
Edwards et al9 identified 19 patients with ESRD who
underwent 25 bypass grafts and had a significantly lower
limb salvage rate than 326 patients without renal disease.
On the basis of these findings, the authors suggested that
primary amputation should be considered in patients who
have ESRD without regard to possible vascular recon-
struction. These conclusions were echoed by Leers et al7
who reviewed their results of pedal bypass grafting in
ESRD. They found only modest limb salvage (50% at 2
years) with two notable trends. First, all patients with heel
gangrene either had early limb loss or died. Second, there
was a high rate of amputation even with a patent bypass
graft, possibly because of other factors besides ischemia,
such as progressive unremitting distal tissue necrosis.
Johnson et al6 and Sanchez et al8 identified similar pat-
terns in patients with ESRD and noted that limb loss,
despite a patent graft, occurred most commonly in the set-
ting of extensive preoperative forefoot gangrene and
ongoing infection. Using this same philosophy, Simsir, et
al19 concluded that more liberal use of primary amputa-
tion in the population with ESRD would improve patient
outcomes.
Conversely, many investigators have thought that
bypass grafting is justified in ESRD because of the devas-
tating consequences of extremity amputation in this
patient population. Baele et al2 reviewed outcomes after
infrainguinal bypass grafting in 44 patients requiring dial-
ysis. They reported a 70% limb salvage rate after 1 year and
concluded that, in selected patients without extensive pre-
operative gangrene, acceptable outcomes were achievable.
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Fig 2. Cumulative secondary patency of nonautogenous infrain-
guinal bypass grafts in patients with ESRD (24) and functioning
kidneys (140). Dashed lines denote SEM > 10%. Difference is sta-
tistically significant (P < .05). ESRD, End-stage renal disease.
Fig 3. Cumulative limb salvage in patients with ESRD (82) and
functioning kidneys (343) undergoing infrainguinal bypass graft-
ing. Difference is statistically significant (P < .01). ESRD, End-
stage renal disease.
In 1990 Chang et al4 demonstrated that limb salvage
could be maintained even in the presence of extensive gan-
grene or ischemic ulceration. Furthermore, Harrington et
al20 reported 84% limb salvage after 3 years in a group of
39 patients with ESRD and concluded that, although the
overall survival was lower in this group, limb revascular-
ization should be considered with the use of the same cri-
teria as for patients with functioning kidneys. Finally,
Whittemore et al21 showed improved overall survival for
patients with ESRD undergoing revascularization (40%) as
compared with primary amputation (5%). 
Conflicting opinions about the safety and efficacy of
infrainguinal bypass grafting in patients with ESRD stim-
ulated the current retrospective study. Some historical
trends were again demonstrated, including similar patency
rates for autogenous conduits in patients with or without
functioning kidneys, despite a higher incidence of comor-
bid conditions in patients with ESRD. Both the limb sal-
vage rate and survival were significantly lower in patients
with ESRD, but 3-year rates exceeding 50% appear to jus-
tify this invasive surgical procedure. Subgroup analysis was
performed to identify patients in whom primary amputa-
tion might well be indicated. Patients who had ESRD with
tissue loss clearly fared worse than those with rest pain,
although the severity of tissue loss was not necessarily pre-
dictive of therapeutic failure. In contrast to other pub-
lished series, the necessity of extremity amputation,
despite a patient bypass graft, was an infrequent finding in
this study. These data would suggest that proper patient
selection for infrainguinal bypass grafting is critical and
that few patients in this series were offered revasculariza-
tion inappropriately.
An additional finding in this study is that the results of
infrainguinal bypass grafting in patients with ESRD appear
to be strongly dependent on conduit choice. The 2-year
secondary patency, limb salvage, and survival in patients
with ESRD having bypass grafts comprised of autogenous
conduits were 79% ± 6%, 72% ± 5%, and 89% ± 4%, com-
pared with 27% ± 12%, 54% ± 13%, and 54% ± 16% in
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patients having nonautogenous conduits. Complication
rates with nonautogenous conduits were also higher,
including four cases of prosthetic graft infection, one of
which was fatal. Of course, the superiority of autologous
tissue for infrageniculate bypass grafting has repeatedly
been demonstrated,22 including recent reports suggesting
that autologous conduits perform better in the above-
knee position as well.23 This concept appears to be partic-
ularly important in patients with renal failure, who
typically have low resistance to infection, poor wound
healing, a high prevalence of concomitant foot infection,
and target arteries with poor outflow.
In conclusion, infrainguinal revascularization can be
performed in dialysis-dependent patients with satisfactory
perioperative and long-term results. This is especially true
for patients presenting with manageable tissue loss and
adequate autogenous conduit. The acceptable rates of
perioperative complication, graft patency, limb salvage,
and patient survival appear to justify infrainguinal bypass
grafting in properly selected patients with renal failure.
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Dr John Corson (Iowa City, Iowa). I was curious why you did
not present any primary patency data. Secondary patency was all
that you presented. Why not tell us the primary patency data?
Dr Christopher Skelly. Our overall primary patency was 55%
± 10% at 3 years. Our primary assisted patency was 56% ± 10% at
3 years as well. Now in the group that we presented, we excluded
all claudicants. The redo rate was 21%, and less than 50% of all
conduits were single segment greater saphenous.
Dr M. Ashraf Mansour (Maywood, Ill). That was very nicely
done. It is a great series from the University of Chicago. I have
three questions. How many patients in your renal failure group
had heel ulcers, and did those patients fare worse than the ones
that, say, had toe ulcers or gangrene in the toes?
The second question is, what was your anesthetic of choice?
Was it an epidural, spinal or general?
Finally, how many of those 80-some patients actually had a
pedal bypass down to the dorsalis pedis or to the distal branches
of the posterior tibial?
Dr Skelly. We did a subanalysis on the location of the tissue
loss for patients with end-stage renal disease and found that in
patients presenting with toe gangrene compared with patients
presenting with heel ulceration, there was actually no difference
in the limb salvage rate.
The choice of anesthetic is generally left to our anesthesia
colleagues. However, the majority of the patients underwent gen-
eral anesthesia. 
Regarding the patients undergoing a very distal bypass, six
patients had a distal anastomosis to the dorsalis pedis artery level
and 20 at the distal posterior tibial artery level.
Dr J. Jeffrey Alexander (Cleveland, Ohio). That was a very
nice paper. We looked at this same issue several years ago at Case
Western Reserve University, and I am struck by the similarity
between the results. One of the things that I noticed from our
patient group was a significantly higher incidence of local wound
complications. That may be due to the fact that we prefer saphe-
nous vein and use it in the majority of patients. We also found that
many of these patients never really returned to what we would
consider a good quality of life despite good graft patency. Of
course, they often did not start off with a good quality of life.
Although we did not address this issue in our paper, I noticed in
talking with a number of these patients that they actually felt that
amputation may have been preferable after undergoing care of
wound complications and in some cases revision or thrombec-
tomy of these bypass grafts. I wonder if you could comment on
that. 
Dr Skelly. In general, patients presenting with forefoot gan-
grene are not subjected to bypass, but actually underwent pri-
mary amputation. Their outcome is not examined in the current
study, which includes only patients undergoing revascularization.
Several studies, one in particular by Raviola et al, a cost analysis of
primary amputation versus revascularization, have reported no
difference in cost. Well-controlled studies comparing lifelong
outcome between primary amputation and revascularization in
this patient group are lacking and would be a welcome addition
to the surgical literature. 
Dr Robert McLafferty (Springfield, Ill). I had a question
regarding the repair utilizing PTFE and was wondering in your
series whether you have gone to the use of vein cuff, either Miller
cuff or Taylor patch. We have a low threshold for doing that when
there is no vein available. 
Dr Skelly. We did use the Taylor patch and other distal mod-
ifications in 29 patients with PTFE. But obviously our first choice
was autogenous conduit.
Dr McLafferty. What is your policy on anticoagulation
regarding vein versus PTFE?
Dr Skelly. In general, patients are not initially anticoagulated
with warfarin. If there is no contraindication, they are given an
aspirin. If the graft fails, then patients are treated with warfarin
hopefully to extend secondary patency.
Dr Timothy Kresowik (Iowa City, Iowa). My question was
actually a follow-up on that last one in that there are a lot of prej-
udices about people with renal failure regarding whether or not
DISCUSSION
they are auto-anticoagulated. Did you actually look at the groups
and see if your anticoagulation regimen was the same in the renal-
failure patients versus the nonrenal-failure patients?
Dr Skelly. We did not look at that.
Dr Fred Littooy (Maywood, Ill). A question about your pros-
thetic grafts. As I looked at your 1-year patencies, it looked like
they were down around 20%. I guess my question is, how many
of those patients actually came to amputation at that time, and
would they have been better served with amputation to start with
and if you are going to see that it is a prosthetic graft situation?
Dr Skelly. You are correct. The 2-year patency was 27% for
those patients with nonautogenous grafts. A patient with end-
stage renal failure, no autogenous conduit, and extensive tissue
loss may well be better served by primary amputation.
Dr W. Kirt Nichols (Columbia, Mo). Nice presentation on a
group of patients with vexing problems that face all of us. This
group of patients does have numerous risk factors including
recurrent exposure to heparin during their dialysis. A small but
very real proportion of these patients may develop heparin-
induced thrombocytopenia at some time during their postopera-
tive period. Did you find any patients with heparin-induced
thrombocytopenia, and do you think this contributed to any of
your graft failures, either early or late?
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Second, also chronic renal failure patients are thought to
have, or many of them have been demonstrated to have, other
risk factors such as hyperhomocysteinemia. Did you look 
for that in any of your patients, and did you treat that group 
of patients?
Dr Skelly. We are actively investigating the influence of coag-
ulation defects in this patient group but have no data as of yet. To
answer your second question about hyperhomocysteinemia, we
did not routinely screen for homocysteine, and no, we did not
actively treat it.
Dr William H. Baker (Maywood, Ill). My approach to this
problem is to send all of them to Dr Littooy and Dr Mansour. In
an effort to help these gentlemen plan their care, how many
patients were alive with a functioning graft and a good leg at 1
year and at 2 years and at 3 years? As I understand it, 50% are dead
and 50% of the grafts are not working. That means there cannot
be too many good results.
Dr Skelly. A more appropriate interpretation of the life table
would be that patient undergoing bypass with autogenous con-
duit exhibited 3-year secondary patency, limb salvage, and sur-
vival rates of 67%, 59%, and 60%. These results appear to justify
an attempt at revascularization in properly selected patients with
end-stage renal failure.
